Predictors of mortality in patients with extensively drug-resistant Acinetobacter baumannii pneumonia receiving colistin therapy

International Journal of Antimicrobial Agents

Volumn 48, Issue 2, 2016, Pages 175-180

  Choi, Ik Sung ^a   Lee, Yu Ji ^a   Wi, Yu Mi ^a,b   Kwan, Byung Soo ^a   Jung, Kae Hwa ^a   Hong, Woong Pyo ^a   Kim, June Myong ^b  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Yonsei University   (South Korea)

Author keywords

Acinetobacter baumannii; Colistin; Pneumonia; Predictor

Indexed keywords

COLISTIN; ANTIINFECTIVE AGENT;

ACINETOBACTER BAUMANNII; ACINETOBACTER BAUMANNII PNEUMONIA; ACINETOBACTER INFECTION; ADULT; AGED; ANTIBIOTIC THERAPY; APACHE; ARTICLE; BACTERIAL PNEUMONIA; CONTROLLED STUDY; DRUG RESPONSE; EXTENSIVELY DRUG RESISTANT ACINETOBACTER BAUMANNII; FEMALE; HUMAN; IDEAL BODY WEIGHT; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MORTALITY RATE; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; SEPTIC SHOCK; SOLID TUMOR; SPUTUM CULTURE; DECISION SUPPORT SYSTEM; DRUG EFFECTS; ISOLATION AND PURIFICATION; MICROBIOLOGY; MIDDLE AGED; MORTALITY; MULTIDRUG RESISTANCE; PATHOLOGY; SURVIVAL ANALYSIS; YOUNG ADULT;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ADULT; AGED; ANTI-BACTERIAL AGENTS; COLISTIN; DECISION SUPPORT TECHNIQUES; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; HUMANS; MALE; MIDDLE AGED; PNEUMONIA, BACTERIAL; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 84979654219     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2016.05.011     Document Type: Article

References (31)

1. [1] Apisarnthanarak, A., Hsu, L.Y., Khawcharoenporn, T., Mundy, L.M., Carbapenem-resistant Gram-negative bacteria: control interventions in resource-limited settings?. Expert Rev Anti Infect Ther 11 (2013), 147–157.
2. [2] Chung, D.R., Song, J.H., Kim, S.H., Thamlikitkul, V., Huang, S.G., Wang, H., et al. High prevalence of multidrug-resistant non-fermenters in hospital-acquired pneumonia in Asia. Am J Respir Crit Care Med 184 (2011), 1409–1417.
3. [3] Evans, M.E., Feola, D.J., Rapp, R.P., Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant Gram-negative bacteria. Ann Pharmacother 33 (1999), 960–967.
4. [4] Falagas, M.E., Kasiakou, S.K., Colistin: the revival of polymyxins for the management of multidrug-resistant Gram-negative bacterial infections. Clin Infect Dis 40 (2005), 333–341.
5. [5] Li, J., Nation, R.L., Turnidge, J.D., Milne, R.W., Coulthard, K., Rayner, C.R., et al. Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect Dis 6 (2006), 589–601.
6. [6] Li, J., Nation, R.L., Milne, R.W., Turnidge, J.D., Coulthard, K., Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria. Int J Antimicrob Agents 25 (2005), 11–25.
7. [7] Dudhani, R.V., Turnidge, J.D., Nation, R.L., Li, J., fAUC/MIC is the most predictive pharmacokinetic/pharmacodynamic index of colistin against Acinetobacter baumannii in murine thigh and lung infection models. J Antimicrob Chemother 65 (2010), 1984–1990.
8. [8] Dudhani, R.V., Turnidge, J.D., Coulthard, K., Milne, R.W., Rayner, C.R., Li, J., et al. Elucidation of the pharmacokinetic/pharmacodynamic determinant of colistin activity against Pseudomonas aeruginosa in murine thigh and lung infection models. Antimicrob Agents Chemother 54 (2010), 1117–1124.
9. [9] Garonzik, S.M., Li, J., Thamlikitkul, V., Paterson, D.L., Shoham, S., Jacob, J., et al. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother 55 (2011), 3284–3294.
10. [10] Knaus, W.A., Draper, E.A., Wagner, D.P., Zimmerman, J.E., APACHE II: a severity of disease classification system. Crit Care Med 13 (1985), 818–829.
11. [11] American Thoracic Society, Infectious Diseases Society of America, Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 171 (2005), 388–416.
12. [12] Devine, B.J., Gentamicin therapy. Drug Intell Clin Pharm 8 (1974), 650–655.
13. [13] Levey, A.S., Stevens, L.A., Schmid, C.H., Zhang, Y.L., Castro, A.F. 3rd, Feldman, H.I., et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 150 (2009), 604–612.
14. [14] Khawcharoenporn, T., Pruetpongpun, N., Tiamsak, P., Rutchanawech, S., Mundy, L.M., Apisarnthanarak, A., Colistin-based treatment for extensively drug-resistant Acinetobacter baumannii pneumonia. Int J Antimicrob Agents 43 (2014), 378–382.
15. [15] Kwon, K.H., Oh, J.Y., Yoon, Y.S., Jeong, Y.J., Kim, K.S., Shin, S.J., et al. Colistin treatment in carbapenem-resistant Acinetobacter baumannii pneumonia patients: incidence of nephrotoxicity and outcomes. Int J Antimicrob Agents 45 (2015), 605–609.
16. [16] Iregui, M., Ward, S., Sherman, G., Fraser, V.J., Kollef, M.H., Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia. Chest 122 (2002), 262–268.
17. [17] Luna, C.M., Aruj, P., Niederman, M.S., Garzón, J., Violi, D., Prignoni, A., et al. Appropriateness and delay to initiate therapy in ventilator-associated pneumonia. Eur Respir J 27 (2006), 158–164.
18. [18] David, M.D., Gill, M.J., Potential for underdosing and emergence of resistance in Acinetobacter baumannii during treatment with colistin. J Antimicrob Chemother 61 (2008), 962–964.
19. [19] Gibson, G.A., Bauer, S.R., Neuner, E.A., Bass, S.N., Lam, S.W., Influence of colistin dose on global cure in patients with bacteremia due to carbapenem-resistant Gram-negative bacilli. Antimicrob Agents Chemother 60 (2015), 431–436.
20. [20] Li, J., Rayner, C.R., Nation, R.L., Owen, R.J., Spelman, D., Tan, K.E., et al. Heteroresistance to colistin in multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 50 (2006), 2946–2950.
21. [21] Rahal, J.J., Novel antibiotic combinations against infections with almost completely resistant Pseudomonas aeruginosa and Acinetobacter species. Clin Infect Dis 43:Suppl. 2 (2006), S95–9.
22. [22] Petrosillo, N., Chinello, P., Proietti, M.F., Cecchini, L., Masala, M., Franchi, C., et al. Combined colistin and rifampicin therapy for carbapenem-resistant Acinetobacter baumannii infections: clinical outcome and adverse events. Clin Microbiol Infect 11 (2005), 682–683.
23. [23] Pantopoulou, A., Giamarellos-Bourboulis, E.J., Raftogannis, M., Tsaganos, T., Dontas, I., Koutoukas, P., et al. Colistin offers prolonged survival in experimental infection by multidrug-resistant Acinetobacter baumannii: the significance of co-administration of rifampicin. Int J Antimicrob Agents 29 (2007), 51–55.
24. [24] Montero, A., Ariza, J., Corbella, X., Doménech, A., Cabellos, C., Ayats, J., et al. Antibiotic combinations for serious infections caused by carbapenem-resistant Acinetobacter baumannii in a mouse pneumonia model. J Antimicrob Chemother 54 (2004), 1085–1091.
25. [25] Saballs, M., Pujol, M., Tubau, F., Peña, C., Montero, A., Domínguez, M.A., et al. Rifampicin/imipenem combination in the treatment of carbapenem-resistant Acinetobacter baumannii infections. J Antimicrob Chemother 58 (2006), 697–700.
26. [26] Aydemir, H., Akduman, D., Piskin, N., Comert, F., Horuz, E., Terzi, A., Colistin vs. the combination of colistin and rifampicin for the treatment of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia. Epidemiol Infect 141 (2013), 1214–1222.
27. [27] Durante-Mangoni, E., Signoriello, G., Andini, R., Mattei, A., De Cristoforo, M., Murino, P., et al. Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: a multicenter, randomized clinical trial. Clin Infect Dis 57 (2013), 349–358.
28. [28] Lo-Ten-Foe, J.R., de Smet, A.M., Diederen, B.M., Kluytmans, J.A., van Keulen, P.H., Comparative evaluation of the VITEK 2, disk diffusion, Etest, broth microdilution, and agar dilution susceptibility testing methods for colistin in clinical isolates, including heteroresistant Enterobacter cloacae and Acinetobacter baumannii strains. Antimicrob Agents Chemother 51 (2007), 3726–3730.
29. [29] Yau, W., Owen, R.J., Poudyal, A., Bell, J.M., Turnidge, J.D., Yu, H.H., et al. Colistin hetero-resistance in multidrug-resistant Acinetobacter baumannii clinical isolates from the Western Pacific region in the SENTRY antimicrobial surveillance programme. J Infect 58 (2009), 138–144.
30. [30] Hawley, J.S., Murray, C.K., Jorgensen, J.H., Colistin heteroresistance in Acinetobacter and its association with previous colistin therapy. Antimicrob Agents Chemother 52 (2008), 351–352.
31. [31] Plachouras, D., Karvanen, M., Friberg, L.E., Papadomichelakis, E., Antoniadou, A., Tsangaris, I., et al. Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by Gram-negative bacteria. Antimicrob Agents Chemother 53 (2009), 3430–3436.